MINNEAPOLIS, MN, Oct. 21, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading provider of biomedical therapeutics for equines and companion animals, has appointed Cindy Gill to the position of field veterinary business development manager for the entire states of Oklahoma and Arkansas and the northern region of Texas. “Cindy’s experience and strong record of sales achievement with veterinary clinics brings to our sales team a valuable resource for achieving our business goals,” ...

Expert Capablites of Senior Vet-Tech to Help Drive Greater Adoption of Spryng as Breakthrough Treatment of Osteoarthritis for Companiaon Animals MINNEAPOLIS, MN, & Annapolis Junction, MD, US, Sept. 09, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading biomedical company delivering innovative therapeutic devices for equines and companion animals, has appointed board certified veterinary surgeon, Dr. Kirsty Husby, DVM, MS, DACVS (LA), to the position of senior technical services ...

MINNEAPOLIS, MN, US, Sept. 03, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals and animal athletes is pleased to announce that Scot Cave has accepted a position with the Company as its new Field Veterinary Business Development Manager to cover the Northwest Region of the United States. "The addition of Scot to our sales and distribu ...

MINNEAPOLIS, MN, US, Aug. 19, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCB: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals and animal athletes is pleased to announce that Anthony Germinaro has accepted a position with the Company as its new Field Veterinary Business Development Manager for the for the Southwest Region of the United States. "Adding Anthony to our sales and distr ...

Core Viewpoint - PetVivo Holdings, Inc. is experiencing growth in revenue and operational milestones, driven by the adoption of its flagship product, Spryng with OsteoCushion technology, and is reiterating its revenue guidance for fiscal 2025, expecting a growth of 50% to 100% compared to the previous year [1][13]. Financial Highlights - Revenues for fiscal Q1 2025 increased by 6% to $124,000, attributed to the rollout of Spryng [3][14]. - Sales to distributors surged by 102% to $68,000, indicating strong demand and expansion of the distributor network [3]. - Gross profit rose by 6% to $111,000, maintaining a gross margin of 89.5% [3][14]. - The net loss improved to $2.0 million or $(0.11) per share, compared to a net loss of $2.9 million or $(0.25) per share in the same quarter last year, due to cost-reduction strategies [3][16]. Operational Highlights - Spryng is now distributed in over 800 veterinary clinics across all 50 states, with more than 10,000 syringes sold [4]. - Key appointments include April Boyce as VP of Marketing and Bryan Monninger as VP of Sales, both bringing extensive experience from major companies [4][8]. - The company showcased Spryng at significant veterinary conferences, enhancing its visibility among industry experts [4][12]. Strategic Outlook - The company plans to accelerate market adoption of Spryng through additional key hires and strengthening its sales and marketing teams [7][9]. - Ongoing clinical studies, including one at Colorado State University, are expected to bolster the product's credibility and support distribution strategies [10][11]. - PetVivo is positioned to capitalize on the growing $5.7 billion U.S. animal health market, projected to reach $11.3 billion by 2030 [13]. Revenue Guidance - For fiscal 2025, the company anticipates net revenue between $1.5 million and $2.0 million, reflecting a growth of approximately 50% to 100% over the prior year [13].

Core Insights - PetVivo Holdings, Inc. has appointed Eric Samples as the new Field Veterinary Business Development Manager, focusing on Ohio, Pennsylvania, and the Baltimore/DC area [1][2] - Eric Samples brings over 25 years of experience in human and animal health sales, having previously worked with Covetrus and other major pharmaceutical companies [2][5] - The company aims to enhance awareness of its flagship product, Spryng™ with OsteoCushion™ technology, which is designed to manage lameness and joint-related issues in animals [2][3] Company Overview - PetVivo Holdings, Inc. is a biomedical device company that specializes in innovative medical devices and therapeutics for companion animals [4] - The company has a strategy focused on developing and commercializing human therapies for companion animals efficiently, allowing for quicker market entry compared to human pharmaceuticals [4] - PetVivo has a robust pipeline of products and holds a portfolio of 21 patents protecting its biomaterials and production processes [5] Product Information - The flagship product, Spryng™ with OsteoCushion™ Technology, is an intra-articular injectable aimed at managing lameness and joint-related afflictions, including osteoarthritis, in various animals [5]

Core Viewpoint - PetVivo Holdings, Inc. will hold a conference call on August 14, 2024, to discuss its fiscal first quarter results for the period ending June 30, 2024, with financial results to be released prior to the call [1]. Company Overview - PetVivo Holdings, Inc. is a biomedical device company focused on innovative medical devices and therapeutics for companion animals, aiming to develop human therapies for animals efficiently [4]. - The company has a robust pipeline of products and holds a portfolio of 21 patents protecting its biomaterials and production processes [5]. Product Information - The flagship product, Spryng™ with OsteoCushion™ Technology, is designed for managing lameness and joint-related issues, including osteoarthritis, in cats, dogs, and horses [5].

Revenue Growth - Revenues increased by 6% to $969,000, primarily driven by sales of the Spryng™ with OsteoCushion™ technology[5] - Sales to distributors rose by 15% to $732,000, contributing significantly to revenue growth[5] - The company expects fiscal 2025 revenues to be between $1.5 million and $2.0 million, representing growth of approximately 50% to 100% over fiscal 2024[13] Profitability and Expenses - Gross profit grew by 6% to $740,000, with gross margin improving by 40 basis points to 76.3%[5][15] - Operating expenses increased by 20% to $11.4 million, mainly due to a rise in general and administrative expenses[15] - Net loss totaled $11.0 million, or $(0.78) per share, compared to a net loss of $8.7 million, or $(0.85) per share in the previous year[16][29] Market Opportunities - The distribution of Spryng has expanded to over 700 veterinary clinics across 50 states, with more than 6,000 syringes distributed[5] - The number of pets insured in North America increased by 20.9% last year, exceeding 6 million, which is expected to drive market growth[12] - The U.S. Animal Health Market is projected to double to $11.3 billion by 2030, presenting significant opportunities for the company[12] Leadership Changes - The company appointed a new CFO and a new board member with extensive experience in the animal health industry to strengthen its leadership[5]

Market Information Dividends From January 2024 to March 2024, the Company issued 324,000 shares of common stock to four consultants for services provided to the Company valued at $333,660. All of these transactions described above were exempt from registration in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended, as a transaction by an issuer not involving a public offering. The purchasers of securities in each of these transactions represented their intention to acquire securities for i ...

Financial Highlights - Revenues increased by 6% to $969,000, primarily driven by sales of the Spryng™ with OsteoCushion™ technology [10][12] - Gross profit rose by 6% to $740,000, with gross margin improving by 40 basis points to 76.3% [10][17] - Operating expenses increased by 20% to $11.4 million, attributed to higher general and administrative expenses and research and development costs [6][41] - Net loss totaled $11.0 million or $(0.78) per share, compared to a net loss of $8.7 million or $(0.85) per share in the previous year [30][41] Operational Highlights - The company expanded its distribution network, achieving distribution of Spryng to over 700 veterinary clinics across 50 states [11] - Sales to distributors increased by 15% to $732,000, contributing significantly to revenue growth [10][12] - The number of pets insured in North America rose by 20.9% to over 6 million, enhancing the affordability of pet care [6] Management Commentary - The management emphasized the positive clinical data supporting the safety and efficacy of Spryng for treating osteoarthritis in companion animals [4][14] - The company is positioning itself for future success by hiring new sales and marketing leadership and expanding personnel to support distribution relationships [5][12] - The management expressed optimism about the growth potential in the $5.7 billion U.S. Animal Health Market, projected to double to $11.3 billion by 2030 [15] Future Outlook - For fiscal 2025, the company anticipates net revenue of approximately $1.5 million to $2.0 million, representing growth of 50% to 100% over the prior year [16] - Plans include further building technical service teams and completing additional clinical studies in equine, canine, and feline companion animals [28]